Jump to: navigation, search
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass215.633 g/mol

WikiDoc Resources for Carisbamate


Most recent articles on Carisbamate

Most cited articles on Carisbamate

Review articles on Carisbamate

Articles on Carisbamate in N Eng J Med, Lancet, BMJ


Powerpoint slides on Carisbamate

Images of Carisbamate

Photos of Carisbamate

Podcasts & MP3s on Carisbamate

Videos on Carisbamate

Evidence Based Medicine

Cochrane Collaboration on Carisbamate

Bandolier on Carisbamate

TRIP on Carisbamate

Clinical Trials

Ongoing Trials on Carisbamate at Clinical

Trial results on Carisbamate

Clinical Trials on Carisbamate at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Carisbamate

NICE Guidance on Carisbamate


FDA on Carisbamate

CDC on Carisbamate


Books on Carisbamate


Carisbamate in the news

Be alerted to news on Carisbamate

News trends on Carisbamate


Blogs on Carisbamate


Definitions of Carisbamate

Patient Resources / Community

Patient resources on Carisbamate

Discussion groups on Carisbamate

Patient Handouts on Carisbamate

Directions to Hospitals Treating Carisbamate

Risk calculators and risk factors for Carisbamate

Healthcare Provider Resources

Symptoms of Carisbamate

Causes & Risk Factors for Carisbamate

Diagnostic studies for Carisbamate

Treatment of Carisbamate

Continuing Medical Education (CME)

CME Programs on Carisbamate


Carisbamate en Espanol

Carisbamate en Francais


Carisbamate in the Marketplace

Patents on Carisbamate

Experimental / Informatics

List of terms related to Carisbamate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Carisbamate (YKP 509) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Pharma (currently SK Holding), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partical seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase 3 clinical trial for the treatment of partial seizures. As of September, 2007, the trial had completed enrollment, but the blind had not been broken. Assuming the the phase III trial demonstrates positive results consistent with the phase II study, the company expects to file for registration in 2008. Its mechanism of action is unknown [1] [2].


  1. Rogawski MA (2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Res. 69 (3): 273–294. PMID 16621450.
  2. Novak GP, Kelley M, Zannikos P, Klein B (2007). "Carisbamate (RWJ-333369)". Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 4 (1): 106–109. PMID 17199023.